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The Performance of Healthcare Mutual Funds 
Abstract 
The objective of this dissertation is to evaluate the performance of actively 
managed US equity healthcare mutual funds and the persistence of these funds. Fund 
performance was evaluated based on the Jensen (1968) and Carhart (1997) 
unconditional measures and also on the full conditional model of Christopherson, 
Ferson and Glassman (1998). Performance persistence was assessed by means of the 
cross-sectional regressions and contingency tables over periods of 6 months, 12 
months and 24 months. The sample comprises 35 US open-end equity sector 
healthcare mutual funds during the period from January 2002 to September 2014. 
Three predetermined public information variables about the state of the economy were 
taken into account to explain the fund returns. 
The results suggest that in general actively managed US equity healthcare 
mutual funds present neutral performance in relation to the Healthcare Index, and 
show better performance in relation to a general market index. We also find some 
evidence of persistence for short periods of 6 months, which tends to disappear for 
periods of 12 and 24 months. These results are consistent with most of the previous 
empirical evidence. 
 
  
iii 
 
The Performance of Healthcare Mutual Funds 
Resumo 
Esta dissertação pretende investigar o desempenho de fundos de investimento 
dos EUA que investem no sector da saúde bem como a persistência destes fundos. O 
desempenho dos fundos é avaliado com base nas medidas não condicionais de Jensen 
(1968) e Carhart (1997) e também com base no modelo totalmente  condicional de 
Christopherson, Ferson e Glassman (1998). A persistência do desempenho é avaliada 
por meio de regressões cross-section e através de tabelas de contingência para períodos 
de 6 meses, 12 meses e 24 meses. A amostra é constituída por 35 fundos de 
investimento dos EUA do sector da saúde para o período de janeiro de 2002 a 
setembro de 2014. Três variáveis de informação pública sobre o estado da economia 
são tidas em conta para explicar as rendibilidades do fundo. 
Os resultados mostram que, em geral, os fundos de investimento do sector da 
saúde apresentam um desempenho neutro relativamente ao índice do sector, mas 
obtêm um desempenho melhor quando avaliados relativamente ao mercado em geral. 
Os resultados mostram alguma evidência de persistência para curtos períodos de 6 
meses, mas que tende a desaparecer para períodos mais longos de 12 e 24 meses. Estes 
resultados são consistentes com a maior parte da evidência empírica anterior. 
…………………………………………
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1 - INTRODUCTION 
 Since their creation, mutual funds have been a popular investment vehicle for 
investors. In 2014, roughly 56.7 million households and 96.2 million individuals in the 
United States own mutual funds (Investment Company Institute, 2014). Thus, it is 
more and more important to evaluate the performance of actively managed mutual 
funds to analyze whether the value of active management compensates the cost of 
professional management. In addition, knowing whether the performance of these 
funds is a random outcome or if it persists over time is an important matter both for 
investors and fund managers. Most of the mutual fund literature investigates the 
abnormal performance and persistence of performance for well-diversified funds, and 
only a few studies evaluate sector-specific funds. 
As the name implies, a sector fund is a mutual fund that invests in a specific 
sector of the economy. Healthcare funds are one of the eight sector funds analyzed by 
Morningstar. These funds can cover any kind of for-profit medical institution, such as 
pharmaceutical companies. Many of these funds also focus on biotechnology and the 
companies that make pioneering advances in this industry. 
The healthcare sector has gone through a substantial growth over the last 
twenty-five years: “Healthcare’s dominance, moreover, is long-lived. The sector held 
up remarkably well during the 2007-2009 bear market. The S&P Health Care index 
was the second top sector during the bloodbath, falling 38.0%, compared with a 55.3% 
tumble for the S&P 500. Since the bear market’s March 9, 2009, nadir, health care 
returned 287.4%, or 24.3% annualized. That beat the S&P 500 by an average of 1.7 
percentage points per year. Health care also performed strongly during the 1990s. Add 
it all up and, health care is the top-performing sector over the past 25 years, with the 
S&P Health Care index returning an annualized 12.3%, compared with 9.6% for the 
S&P 500” (Kiplinger, 2015). Besides, the demand for better healthcare is growing in 
the developed world and the healthcare products and services are necessary, thus 
stocks in the healthcare sector are considered to be defensive. The healthcare sector is 
likely less sensitive to business cycle fluctuations, as a stabilizing sector. According to 
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the commentary about mutual funds of Zacks Investment Research (2015) “The 
healthcare sector is one of the most desirable avenues for parking investments when 
markets are headed south. The demand for such services usually remains unchanged 
even during an economic downturn and investments in the sector provide sufficient 
protection to the capital invested. Several pharmaceutical companies also provide 
regular dividends, which can help mitigate losses from falling share price. Healthcare 
mutual funds provide the perfect avenue for investors looking to invest in this sector”. 
Yet, there are very few studies on healthcare funds. This research focuses on the 
evaluation of the performance of actively managed healthcare mutual funds and the 
persistence of these funds in the period from January 2002 to September 2014. 
The conditional performance evaluation methodologies we use to assess 
healthcare fund performance are considered theoretically robust. The bias of traditional 
models that results from ignoring time-varying estimates of risk and/or performance 
has led to conditional models being adopted for performance evaluation. Public 
information variables about the state of the economy that are available to investors are 
used in these conditional models in such a way that expected returns and risk vary 
throughout time as public information changes. Ferson and Schadt (1996) and 
Christopherson, Ferson and Glassman (1998) suggest that the inclusion of conditioning 
information sharpens inferences on performance. Christopherson, Ferson and 
Glassman (1998) also suggest that the persistence phenomenon is better assessed when 
conditional models of performance evaluation are used.  
The remainder of this dissertation is organized as follows: In chapter 2, we 
provide a relevant literature review on the performance of healthcare mutual funds, as 
well as on the persistence of performance. In chapter 3, we present the methodology 
used. The data will be described in chapter 4. In chapter 5 we examine the empirical 
results. In the last chapter, we conclude our findings.  
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2 – LITERATURE REVIEW 
The performance evaluation literature regarding actively managed mutual 
funds has been broadly debated in the last few decades, and is a critical aspect in 
investors’ decisions. The first studies using risk-adjusted performance measures 
(Treynor, 1965, Sharpe, 1966 and Jensen, 1968) and most subsequent studies found 
empirical evidence showing the inability of active equity funds to outperform market 
indexes. Malkiel (1995) studies US equity mutual funds from 1971 to 1991 and 
concludes that mutual funds tend to underperform the market not only when returns 
are gross of all expenses (except load fees) but also after deducting management fees. 
Kjetsaa (2004) examines mutual funds from Morningstar. He finds that the 
performance of actively managed mutual funds before expenses is equal to the average 
market return, and also finds that the performance after expenses is less than the 
market by roughly the amount of investment expenses. In another study, Karoui and 
Meier (2009) examine the performance and portfolio characteristics of 828 newly 
launched US equity mutual funds, and they find that these funds start initially by 
earning higher excess returns and positive abnormal returns but after some time 
performance declines. Studies that evaluate the performance of mutual funds by using 
conditional measures of performance (such as Ferson and Schadt, 1996) also do not 
find evidence that mutual funds can outperform the market. 
Besides analyzing overall performance, academics and practitioners also have 
investigated whether past performance predicts future performance or not. In fact, 
some studies have assessed performance persistence of general equity mutual funds in 
order to analyze portfolio managers’ abilities to consistently generate good or bad 
performance. Grinblatt and Titman (1992) study US equity funds between 1974 and 
1984. They find evidence that there is positive persistence in mutual fund performance 
by using cross-section regressions between estimated alphas of two periods of five 
years. Goetzmann and Ibbotson (1994) analyze a sample of 728 mutual funds for the 
period from 1976 to 1988 and also find evidence of persistence in performance at time 
horizons from one month to three years. They apply both Chi-square tests and cross-
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sectional regressions to test the persistence of these funds. Khan and Rudd (1995) 
examine the performance persistence of US equity mutual funds and fixed-income 
mutual funds using cross-section regression analysis and contingency tables 
approaches. They show evidence of persistence only for fixed-income fund 
performance. Brown and Goetzmann (1995) also find evidence of relative risk-
adjusted performance persistence of US equity mutual funds for the period from 1976 
to 1988 by using the Odds Ratio Z-statistic. Malkiel (1995) examines the performance 
persistence of equity mutual funds over period from 1971 to 1991 by constructing a Z–
test. His results show evidence of persistence performance during 1970s, and no repeat 
winners during the 1980s. Jan and Hung (2004) examine the performance persistence 
of 3316 US equity funds for the period January 1961 to 2000. They suggest that 
investors can benefit from selecting mutual funds on the basis of both short term and 
long term performances. Silva, Cortez and Armada (2005) focus their study on the 
European market with a sample of 638 bond funds over the period from 1995 to 2000. 
By using contingency tables and cross-sectional regressions the authors find evidence 
of persistence primarily in the Spanish, French and German.  
While the performance and persistence of performance of general equity funds 
has been extensively studied, the performance and performance persistence of sector 
specific funds has been less explored in the literature. These funds invest 
fundamentally in equity shares of companies in a particular business sector or industry. 
While these funds may give higher returns, they are riskier as compared to some well-
diversified funds. For instance, Khorana and Nelling (1997) analyze a sample of 147 
sector funds and document that these funds do not significantly outperform other 
general equity funds. Moreover, they do not find repeat performance of their sample of 
sector funds. Also, they observe that sector funds have higher risk than general equity 
funds. Nevertheless, in another study Burlacu and Fontaine (2003) examine 102 
European sector funds and find that these funds outperform well-diversified funds. 
Considering the performance of special sector funds, Kaushik and Pennathur 
(2012) find empirical evidence of mixed results of over and under – performance in 
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real estate mutual funds. However, the results of Lin and Yung (2004) indicate that on 
average real estate mutual funds do not provide positive abnormal performance. 
Additionally, Lin and Yung (2004) also show that fund performance persists in the 
short term by using the autocorrelation analysis. 
There are just a few studies specifically on the performance of healthcare 
mutual funds. Kaushik, Barnhart and Pennathur (2010) analyze around 1500 sector 
funds including healthcare funds over the period 1990-2005. They find that healthcare 
sector funds outperform the market. These results were also observed in recession 
periods. However, they ignore the longest recession since the end of the Great 
Depression. 
More recently, Kaushik, Saubert and Saubert (2014) analyze 115 US healthcare 
mutual funds over the period 1/2000-12/2011. They show that, on average, healthcare 
mutual funds outperform the passive index and that the abnormal over- and under-
performances are mean reverting. Therefore, they suggest that retail investors can add 
value to their overall portfolio by including a portion of their investment in healthcare 
funds. Further, this study documents that the abnormal over-and under-performance 
does not persist over subsequent periods. 
Given these few studies on healthcare funds, this dissertation aims to contribute 
to the literature by evaluating the performance of these types of funds, which have a 
very specific level of risk and returns. 
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3 - METHODOLOGY 
3.1. Performance measures: Unconditional and Conditional models 
In order to evaluate the performance of mutual funds, we start by using the 
Jensen (1968) measure, which is based on an unconditional single factor model. This 
measure is the intercept of the following regression: 
rp,t = αp + βprm,t + εp,t (1) 
Where rp,t represents the excess return relative to the risk-free rate; αp  
represents the measure of unconditional performance (Jensen’s α); rm,t represents the 
excess return on the market; βp represents the unconditional measure of systematic 
risk. 
After nearly three decades, Fama and French (1993) introduced the three factor 
model using market excess returns, size and book-to-market ratio as factors. 
Academics consider that the three factor model is better than traditional CAPM in 
capturing the relationship between risk and return. Furthermore, Carhart (1997) added 
the momentum factor to the Fama and French (1993) three factor model which results 
in the four factor model: 
rp,t  = αp + β1prm,t+ β2p(SMBt) + β3p (HMLt) + β4p (MOMt) + εp,t (2) 
Where rp,t represents the excess returns relative to the risk-free rate; αp is the 
measure of the portfolio’s performance; rm,t represents the excess return on the market, 
SMBt (Small minus big) is the difference in returns between a portfolio of small and a 
portfolio of large capitalization stocks; HMLt (High minus low) is the difference in 
returns between portfolio of high book-to-market stocks and a portfolio of low book-
to-market stocks; MOMt (Momentum) is the difference in the return between a 
portfolio of stocks of past winners and a portfolio of stocks of past losers. 
We will also evaluate the performance of healthcare funds based on the 
unconditional four factor model of Carhart (1997), estimated by using equation (2). If 
the alpha is positive, the funds do better than anticipated, whereas a negative alpha 
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indicates underperformance relative to the benchmarks: the market, size, book-to-
market, momentum factors. 
Unconditional models of performance evaluation tend to produce incorrect 
performance estimates because they assume that expected returns and risk are invariant 
over time regardless of market conditions. However, both expected returns and risk are 
time-varying. 
In the conditional performance evaluation framework, fund managers’ risk 
exposures and the related market premiums are allowed to vary over time by using 
predetermined public information variables. This is consistent with semi-strong form 
of market efficiency of Fama (1970). Ferson and Schadt (1996) developed a 
conditional model of performance evaluation in which beta is a linear function of a 
vector of predetermined information variables (Zt-1): 
βp (Zt-1) = β0p +β’p  zt-1 (3) 
Where zt-1 = Zt-1 – E(Z) is a vector of the deviations of Zt-1 from the 
(unconditional) average values; β’p is the vector that measures the response of the 
conditional beta to the public information variables; β0p is an average beta, which 
represents the (unconditional) mean of the conditional betas. 
Replacing the conditional beta in equation (1), it follows that: 
rp,t = αp + β0p rm,t + βp’ (zt-1 rm,t)  + εp,t (4) 
Where αp measures the conditional alpha. If a portfolio manager uses only 
publicly available information, represented by Zt-1, the conditional alpha should be 
expected equal to zero. 
Christopherson, Ferson and Glassman (1998) extended the partial conditional 
model by also allowing alphas to be time-varying. 
The conditional alpha function is given by: 
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αp (Zt-1) = α0p + A’pzt-1 (5) 
Where α0p is an average alpha; A’p is a vector that measures the response of the 
conditional alpha to the information variables. Uniting equation (4) and (5) gives a 
conditional single-factor model: 
rp,t  = α0p + Ap’ zt-1 + β0prm,t+ β’p (zt-1 rm,t) + εp,t (6) 
Regression (6) can also be easily extended to a multi-factor framework that 
results in a conditional multi-factor model with time-varying alphas and betas: 
rp,t  = α0p + Ap’ zt-1 + β0p λk,t+ β’p (zt-1 λk,t) + εp,t (7) 
Where β0p is an average beta, which represents the (unconditional) mean of the 
conditional betas; λk,t is the vector of factor returns. 
This dissertation will use three predetermined information variables used by 
Ferson and Schadt (1996) to explain fund returns: the lagged measure of the level of 
short-term interest rate (TB), the lagged measure of the slope of the term spread (TS) 
and the lagged dividend yield of a market index (DY). The full conditional version of 
the single factor model including these predetermined information variables is 
represented in the following way: 
rp,t  = αp0 + αp,tbTBt-1 + αp,tsTSt-1 + αp,dyDYt-1 + βp0 rm,,t+ βp,tb (TBt-1 rm,t) + βp,ts 
(TSt-1 rm,t) + βp,dy (DYt-1 rm,t)  +  εp,t 
(8) 
The full conditional version of the four factor model with the three public 
information variables which was mentioned before is given by following equation: 
rp,t  = αp0 + αp,tbTBt-1 + αp,tsTSt-1 + αp,dyDYt-1 + βp0 rm,,t+ βp,tb(TBt-1 rm,t) + βp,ts(TSt-1 
rm,t) + βp,dy(DYt-1 rm,t) + βp,s(SMBt) + βp,s,tb[TBt-1 (SMBt)] + βp,s,ts[TSt-1 (SMBt)] + 
βp,s,dy[DYt-1 (SMBt)] + βp,h(HMLt) + βp,h,tb[TBt-1 (HMLt)] + βp,h,,ts[TSt-1 (HMLt)] + 
βp,h,dy[DYt-1 (HMLt)] + βp,m(MOMt) + βp,m,tb[TBt-1 (MOMt)] + βp,m,,ts[TSt-1 
(9) 
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(MOMt)] + βp,m,dy[DYt-1 (MOMt)]  +  εp,t 
To test heteroskedasticity and autocorrelation of the residuals of the regressions 
we use the White (1980) test and the Breusch (1978) - Godfrey (1978) test, 
respectively. If both of these phenomena exist or only autocorrelation exists, we will 
adjust the t-statistics of the regressions by following the procedure of Newey and West 
(1987). However, if only heteroskedasticity exists, the White (1980) procedure will be 
used. 
 
3.2. Performance persistence 
There are various methodologies to assess performance persistence: cross-
sectional regressions (Grinbatt and Titman, 1992; Khan and Rudd, 1995); portfolios 
ranked on the previous year performance (Elton, Gruber and Blake, 1996; Huij and 
Derwall, 2008) and contingency tables (Brown and Goetzmann, 1995; Kahn and Rudd, 
1995; Malkiel 1995). 
This dissertation will use both the cross-sectional regressions and contingency 
tables methodologies to assess the persistence performance of healthcare mutual funds. 
Performance persistence is assessed over period of 6 months, 12 months and 24 
months. Monthly alphas are computed in a procedure similar to Ferreira, Keswani, 
Ramos and Miguel (2013) by using the unconditional four factor model with the Dow 
Jones US Healthcare Index as benchmark. For each fund, we run a rolling window 
regression on the previous 24 month periods, and obtain estimated betas coefficients 
relative to the risk premium, SMB, HML, and MOM for each period. In each month, 
equilibrium returns are calculated with the coefficients obtained before, as follows: 
requilibrium,p,t  = rf,t +    1,p,t rm,t+    2,p,t (SMBt) +   3,p,t (HMLt) +   4,p,t (MOMt) (10) 
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Where requilibrium,p,t is the expected return in month t;   1,p,t,   2,p,t ,   3,p,t,   4,p,t are 
coefficients obtained from estimating the four factor model using the previous 24 
month  returns. 
Then, alpha in each month is computed as the difference between the realized 
(discrete) return and the expected equilibrium return. By calculating cumulative alpha 
returns, we get the alphas for 6, 12 and 24 month periods. 
 
3.2.1. Cross–sectional regressions 
In the cross-sectional regression approach, future performance is regressed on 
past performance. The null hypothesis of no persistence of performance will be 
rejected if the slope coefficient in this regression has a significant positive t-statistic. 
Khan and Rudd (1995), Silva, Cortez and Armada (2005) and Huij and Derwall (2008) 
also used this methodology to determine the performance persistence. 
For each period, we calculate slope coefficient bt of the regression using the 
performance of each fund in period t as the dependent variable and the performance of 
each fund in period t-1 as the independent variable, as follows: 
  p,t =  t +  t  p,t-1 + εp,t (11) 
Where   p,t  and   p,t-1 represent performance estimates (cumulative alpha for 6, 
12 and 24) in period t and t-1, respectively. 
The procedure for computing t-statistic follows the methodology of Fama and 
MacBeth (1973): 
T = 
 ̅
   √ ⁄
 (12) 
Where  ̅ and   ̅ respectively are the average and the standard deviation of the 
time series of at or bt. N is the number of periods in the cross-sectional regression.  
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3.2.2. Contingency tables 
An alternative non-parametric methodology is based on contingency tables, in 
which funds are categorized as winners (W) and losers (L) over successive periods. 
Winners have performance above the median performance and losers have 
performance below the median performance in each sub-period. Therefore, 
contingency tables show the frequency with which winners and losers repeat. Evidence 
that winners in one period remain winners in the subsequent period indicates 
persistence of performance, meaning that the null hypothesis of no performance 
persistence is rejected. In this dissertation, we apply three statistical tests to investigate 
performance persistence: Malkiel’s (1995) Z –test for percentage of repeated winners, 
Brown and Goetzmann’s (1995) Odds Ratio Z - statistic, and Kahn and Rudd’s (1995) 
Chi – square statistic.  
In the first test, Malkiel (1995) shows the percentage of repeated winners 
(WW) as follows: 
Percentage of repeated winners = 
  
     
 x 100% (13) 
Then, Malkiel (1995) constructs a Z–test that follows a binominal distribution 
of p >  
 
 
 to check the significance of the proportion of WW to (WW + WL) and LL to 
(LL + LW). Thus, we have: 
Zwinners = 
  	 (  	 	  )	∗	 . 	
 (  	 	  )	∗	 . 	∗	( 	 	 . )
 (14) 
Zlosers = 
  	 (  	 	  )	∗	 . 	
 (  	 	  )	∗	 . 	∗	( 	 	 . )
 (15) 
Where Z is the statistical variable having a normal distribution (0, 1); WW and 
LL are respectively the number of repeat winners and repeat losers; WL and LW are 
respectively the number of funds that are winners in one period then losers in the next 
period and vice versa. 
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The null hypothesis will be rejected if we get a percentage of repeated winners 
or losers greater than 50% and a Z–statistic above zero. This shows the evidence of 
performance persistence, with a significant level of 5%. 
The second test used is to calculate the Odds ratio. 
 Odds ratio = (WW*LL)/ (WL*LW). (16) 
According to the null hypothesis that performance in the first period is 
unrelated to performance in the second period, the Odds ratio will need to be 1. The 
value of an Odds ratio higher than 1 indicates that winners in one period will also 
remain winners in the subsequent period. However, when the Odds ratio is less than 
one, there is negative persistence or reversals (funds are winners in first period and 
losers in the next period and vice versa). To assess the statistical significant of the 
Odds ratio, Brown and Goetzmann (1995) use a Z-statistic, which is the logarithmic 
Odds ratio divided by its standard error. 
Z-statistic = 
  (    	     )
 
 
  
 	
 
  
 	
 
  
	 	
 
  
 (17) 
The log of the estimated Odds ratio is asymptotically normal distributed under 
the assumption of independence of the observations. 
The final statistical test is Chi-square statistic proposed by Kahn and Rudd 
(1995). 
χ2 = 
(   
 
 
)  	(   
 
 
)  	(   
 
 
)  	(   
 
 
) 	
 
 
 (18) 
  Where N is the number of funds. 
According to Carpenter and Lynch (1999), the Chi-square test is very accurate, 
powerful and more robust to the presence of survivorship bias when compared to other 
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tests of performance. To adjust the small sample bias, we use Yates’s continuity 
correction (Cortez, Paxson and Armada, 1999): 
For a general 2x2 table in the format: 
a b 
N = a + b + c + d (19) 
c d 
The observed frequencies are equal to: 
χ2 = 
 (     ) 
(   )(   )(   )(   )
 (20) 
The equation for the Yates’ continuity correction is as follows: 
χ2 = 
 (|     |  .  ) 
(   )(   )(   )(   )
 (21) 
This reduces the chi-squared value obtained and thus increases its P-value.  
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4 - DATA 
This dissertation aims to assess US open-end equity sector healthcare mutual 
funds during the period of January 2002 to September 2014. The data on US 
healthcare equity mutual funds was extracted from the Center for Research in Security 
Prices (CRSP) Survivor-Bias-Free US Mutual Fund Database. The end-of-month 
discrete returns were collected for each of the funds classified as Health/Biotechnology 
funds according to the Lipper classification. This resulted in a list of 110 Health/Bio-
technology funds.  
After having the initial list funds, we excluded all funds with less than 24 
monthly observations as well as Exchange Traded Funds (ETF). In case a fund has 
several share classes, we considered the oldest class and, if necessary, the one having 
the highest total net assets. In total, only 35 equity sector healthcare funds satisfy these 
conditions. They are presented in Appendix 1. 
An equally weighted portfolio and a value weighted portfolio of healthcare 
funds are constructed in order to see if there are any differences in the performance of 
both types of portfolios. Descriptive statistics of these portfolios are showed in table 1. 
On average, the excess returns of the equally weighted portfolio and the value 
weighted portfolio are positive. The hypothesis of normally distribution is rejected for 
both portfolios. The rejection of this hypothesis supports the use of conditional models 
of performance evaluated, as shown by Adcock, Cortez, Armada and Silva (2012). 
The risk-free rate was proxied by the 1-month nominal US government 
securities Treasury constant maturities and extracted from the Federal Reserve1. 
Other data such as the risk premium, SMB factor, HML factor and MOM 
factor was extracted from the website of Professor Kenneth R. French2. 
1 http://www.federalreserve.gov/releases/h15/data.htm 
2 http://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data_library.html 
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Table 1 – Summary statistics of the portfolios 
This table presents the descriptive statistics of the excess monthly returns of equally weighted portfolio 
and value weighted portfolio. The period of analysis is from January 2002 to September 2014. P-value 
(JB) is the probability for a statistical test that the Jarque-Bera statistic exceeds (in absolute value) the 
observed value under the null hypothesis of a normally distribution. 
 Equally Weighted Portfolio Value Weighted Portfolio 
Mean 0.0081 0.0085 
Median 0.0124 0.0122 
Maximum 0.1037 0.1174 
Minimum -0.1451 -0.1581 
Std. Dev. 0.0414 0.0445 
Skewness -0.4980 -0.5103 
Kurtosis 3.5743 3.6975 
Jarque-Bera (JB) 8.4252 9.7426 
P-value (JB) 0.0148 0.0077 
Sum 1.2324 1.2976 
Sum Sq. Dev. 0.2602 0.3014 
Observations 153 153 
 
As the market benchmark, two indexes are used:  a general market index and 
style index. The purpose of using these two indexes is to evaluate fund performance 
relative to the market as a whole and relative to the Health care/Biotechnology sector. 
The market index from Professor Kenneth French’s website is used as a general 
market index. The Dow Jones US Healthcare Index, which was extracted from 
Datastream, is used as a style index. 
Table 2 presents summary statistics for the benchmarks and three risk factors 
over the sample period. On average, the market excess returns and risk factors excess 
return are positive. The hypothesis of normally distribution is rejected for all 
benchmarks and factors, except for the size factor. 
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Table 2 – Summary statistics of benchmarks 
This table presents the descriptive statistics of the excess monthly returns of two benchmarks: Dow 
Jones US Healthcare Index, general market index, and three risk factors: SMB factor, HML factor and 
MOM factor. The period of analysis is from January 2002 to September 2014. P-value (JB) is the 
probability for a statistical test that the Jarque-Bera statistic exceeds (in absolute value) the observed 
value under the null hypothesis of a normally distribution. 
 
Dow Jones 
Index 
Market 
Index 
SMB HML MOM 
Mean 0.0060 0.0056 0.0026 0.0022 0.0008 
Median 0.0085 0.0118 0.0011 0.0004 0.0035 
Maximum 0.0945 0.1135 0.0590 0.0765 0.1245 
Minimum -0.1258 -0.1723 -0.0522 -0.0967 -0.3458 
Std. Dev. 0.0377 0.0438 0.02397 0.0235 0.0494 
Skewness -0.4982 -0.6695 0.1382 -0.4356 -2.5965 
Kurtosis 3.8962 4.3640 2.5822 5.2392 18.4540 
Jarque-Bera (JB) 11.4486 23.2913 1.5996 36.8022 1694.435 
P–value (JB) 0.0033 0.0000 0.4494 0 0 
Sum 0.9221 0.8512 0.3979 0.3402 0.1269 
Sum Sq. Dev. 0.2158 0.2920 0.0873 0.08366 0.3715 
Observations 153 153 153 153 153 
 
The predetermined public information variables that are used in the conditional 
model are: a lagged measure of the level of short term interest rates, a lagged measure 
of the slope of the term structure, and a lagged measure of the dividend yield. These 
variables have been shown by some previous studies such as Fama and French (1989), 
Pesaran and Timmermann (1995), Gallagher and Jarnecic (2004) and Leite, Cortez and 
Armada (2009) to be useful in predicting stock returns. The yield on a constant - 
maturity 3-month US Treasury bill is used as the short-term interest rate. The term 
spread is measured through the difference between the US constant 10-year Treasury 
bond yield and the 3-month Treasury bill. These data were extracted from the Federal 
Reserve website. The dividend yield is based on the Standard and Poors 500 
Composite Dividend Yield and was extracted from Datastream.  
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We apply the stochastic detrending process suggested by Ferson, Sarkissian 
and Simin (2003) to avoid spurious regressions. Accordingly, each predetermined 
public information variable was subtracted from their 12 months moving average. 
These variables are used in their mean zero form. Table 3 presents some descriptive 
statistics for the public information variables.  
Table 3 - Summary statistics of predetermined public information variables 
This table presents some descriptive statistics for the lag information variables for the period of January 
2002 to September 2014: short term interest rates, the slope of the term structure and the dividend yield. 
P-value (JB) is the probability for a statistical test that the Jarque-Bera statistic exceeds (in absolute 
value) the observed value under the null hypothesis of a normally distribution. 
 
Short term interest 
rates 
The slope of the 
term structure 
Dividend yield 
Mean 0.0107 -0.0117 -0.0001 
Median 0.0903 -0.0297 -0.0146 
Maximum 1.1086 1.5437 0.9204 
Minimum -2.3255 -1.0697 -0.7571 
Std. Dev. 0.6190 0.5951 0.2520 
Skewness -0.8301 0.2823 0.3826 
Kurtosis 4.6351 2.485 7.2838 
Jarque-Bera 34.6164 3.7226 120.72 
P-value (JB) 0 0.1555 0 
Sum 1.6397 -1.7953 -0.0170 
Sum Sq. Dev. 58.2431 53.8216 9.6493 
Observations 153 153 153 
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5 – EMPIRICAL RESULTS 
In this chapter, we present and analyze the results on the performance and 
performance persistence of 35 US equity healthcare mutual funds, over the period 
from January 2002 to September 2014. The performance of these funds is analyzed at 
the aggregate level by using an equally weighted portfolio and a value weighted 
portfolio, as well as at the individual fund level. Two market benchmarks are used for 
each model: a general market index and a style index. Performance is first analyzed by 
means of unconditional models and afterwards by conditional models. The 
performance persistence is assessed by using two methodologies: cross-sectional 
regressions and contingency tables.    
5.1. Unconditional and conditional models of performance evaluation 
5.1.1. Unconditional models of performance evaluation 
First, we use unconditional models to evaluate the performance of the dataset 
of funds. The results of fund performance using the unconditional single and four 
factor models are displayed in table 4 and table 5, respectively. In each table, panel A 
presents the results of regressions using the Dow Jones US Healthcare Index as 
benchmark and panel B the results of using the general market index as benchmark. 
We use the Newey and West (1987) procedure to adjust the errors for autocorrelation 
and heteroskedasticity and the White (1980) to correct only in the case of 
heteroskedasticity. 
In general, funds show neutral performance. In both of the two tables, the 
equally weighted and value weighted portfolios exhibit neutral performance relative to 
the Healthcare Index. Most of funds present positive alphas but just few of them are 
significant at a 5% level. In table 4, panel A displays 3 individual funds out of 27 
funds having positive alphas that are statistically significant at a 5% level, and 2 out of 
8 funds having negative alphas that are statistically significant at a 5% level; Fund 
performance is slightly higher when assessed relative to the general market index. 
Indeed, panel B shows that 5 out of 34 individual funds with positive alphas are 
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statistically significant at a 5% level, and only 1 fund with negative alpha but not 
statistically significant. 
Table 4 – Fund performance using the unconditional single model 
This table presents regression estimates for both equally weighted portfolios and value weighted 
portfolios with the Dow Jones US Healthcare Index as benchmark (panel A) and the general market 
index as benchmark (panel B) using the unconditional single model during period from 31/01/2002 to 
30/09/2014. It shows abnormal performance estimates (alpha), systematic risk (beta) and the adjusted 
coefficient of determination (Adj. Rsq). Standard errors are corrected, whenever appropriate, for the 
presence of heteroskedasticity using the correction presented by White (1980), or for the presence of 
autocorrelation and heteroskedasticity using the procedure suggested by Newey and West (1987). t-
statistics are presented in parenthesis. Asterisks (***, **, *) indicate statistically significant values at the 
1%, 5% and 10% levels, respectively. The number of individual funds presenting positive (N+) and 
negative (N-) alphas is reported, the number of those which are statistically significant at the 5% level 
are reported in brackets.  
 
 αp βp Adj Rsq 
Panel A: Benchmark Dow Jones US 
Healthcare Index 
   
Equally weighted portfolio 0.0019 1.0242 86.89% 
 (1.535) (31.762)***  
Value weighted portfolio 0.0020 1.0735 82.41% 
 (1.315) (26.707)***  
N + 27 (3)   
N - 8 (2)   
    
Panel B: General Market Index    
Equally weighted portfolio 0.0038 0.7739 65.24% 
 (1.914)* (16.921)***  
Value weighted portfolio 0.0041 0.7943 60.88% 
 (1.790)* (15.413)***  
N + 34(5)   
N - 1(0)   
 
From panel A of table 5 we observe that there are 25 funds having positive 
alphas, with 4 of them being statistically significant, and 10 funds having negative 
alphas with only 2 of them being statistically significant. Panel B of table 5 shows 10 
out of 34 funds having positive alphas which are significant at a 5% level, and only 1 
fund presenting a negative alpha, although not being statistically significant. These 
results show that in general US healthcare mutual funds have neutral performance 
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relative to the Healthcare Index and that they tend to perform better when compared 
against the general market index. Indeed, the performance of the equally and value 
weighted portfolios is positive and statistically significant at a 5% level when we 
applied the unconditional four factor model with a general market index as benchmark. 
As expected, by using the Dow Jones US Healthcare Index as benchmark we 
get higher adjusted coefficients of determination than using the general market index 
as benchmark. Also, the equally weighted portfolio has an adjusted R2 greater than that 
obtained with the value weighted portfolio. Additionally, the explanatory power of the 
unconditional four factor model is higher than the unconditional single model. 
The coefficients for the market are always positive and statistically significant 
at a 1% level, thus indicating a strong positive correlation between funds and market 
returns. The coefficients for SMB factor of the portfolios are positive and statistically 
significant at a 1% level in the regression using the Dow Jones Index as the 
benchmark, suggesting that portfolios have exposure to small stocks. The coefficients 
of the HML factor are negative and statistically significant at a 1% level, thus 
indicating that the portfolios are mainly exposed to growth stocks. The coefficients of 
MOM factor are not statistically significant. Based on the Wald test, the null 
hypothesis that the coefficients of the market, size (SMB), book-to-market (HML), and 
momentum (MOM) factors are jointly equal to zero is rejected for all portfolios.  
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Table 5 – Fund performance using the unconditional four factor model 
This table presents regression estimates for both equally weighted portfolios and value weighted portfolios with the Dow Jones US Healthcare Index as benchmark (panel A) 
and the general market index as benchmark (panel B) using the unconditional Carhart (1997) four factor model during period from 31/01/2002 to 30/09/2014. It shows 
abnormal performance estimates (alpha), systematic risk (beta), the regressions coefficients of Size (p,s), Value (p,h), and Momentum (p,m) factors and the adjusted 
coefficient of determination (Adj. Rsq). Wald indicates the result of the Wald test for the null hypothesis that the coefficients of the market, size, book-to-market and 
momentum factors are jointly equal to zero. Standard errors are corrected, whenever appropriate, for the presence of heteroskedasticity using the correction presented by 
White (1980), or for the presence of autocorrelation and heteroskedasticity using the procedure suggested by Newey and West (1987). t-statistics are presented in parenthesis. 
Asterisks (***, **, *) indicate statistically significant values at the 1%, 5% and 10% levels, respectively. The number of individual funds presenting positive (N+) and 
negative (N-) alphas is reported, the number of those which are statistically significant at the 5% level are reported in brackets.  
 
 αp βp,0 βp,s βp,h βp,m Adj Rsq Wald 
Panel A: Benchmark Dow Jones US 
Healthcare Index 
 
  
  
  
Equally weighted portfolio 0.0014 0.9891 0.4094 -0.1704 -0.0086 92.51% 470.617*** 
 (1.512) (38.168)*** (10.448)*** (-4.246)*** (-0.433)   
Value weighted portfolio 0.0017 1.0376 0.4399 -0.2752 -0.0123 88.75% 300.651*** 
 (1.381) (30.348)*** (8.509)*** (-5.198)*** (-0.472)   
N + 25 (4)       
N - 10 (2)       
        
Panel B: General Market Index        
Equally weighted portfolio 0.0040 0.7856 0.1265 -0.3165 0.0287 68.19% 71.357*** 
 (2.051)** (12.351)*** (1.227) (-3.152)*** (0.431)   
Value weighted portfolio 0.0045 0.8234 0.1436 -0.4282 0.0265 65.55% 73.294*** 
 (2.077)** (14.184)*** (1.490) (-4.604)*** (0.554)   
N + 34 (10)       
N - 1(0)       
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5.1.2. Conditional models of performance evaluation 
To avoid the bias of unconditional models that results from ignoring time-
varying estimates of risk, the performance of the portfolios is evaluated by using the 
full conditional model of Christopherson, Ferson and Glassman (1998), which 
considers not only the time-varying betas but also time-varying alphas. The 
conditional approach is applied to the single index model and to the Carhart (1997) 
four factor model. 
The performance results using the conditional single index and the conditional 
four factor models are displayed in tables 6 and table 7, respectively.  
Once again, we find that the performance of the portfolios using the general 
market index as benchmark is better than that obtained when using the Dow Jones US 
Healthcare Index. 
Similar to the unconditional models, most individual funds show neutral 
performance. In table 6, we observe that 34 out of 35 funds have positive alphas, with 
13 being statistically significant when using the general market index as benchmark. 
Only 1 fund has negative alpha but it is not statistically significant. When using the 
Dow Jones US Healthcare Index as benchmark, there are 28 funds having positive 
alphas, with 4 of them being statistically significant. Besides, seven funds have 
negative alphas, with 2 of them being statistically significant.  
In table 7 we observe that when using the general market index benchmark, all 
35 funds have positive alphas, and 14 of those alphas are statistically significant at a 
5% level. When using the Dow Jones US Healthcare Index as benchmark, there are 27 
funds having positive alphas, with 6 of them are statistically significant at a 5% level. 
Additionally, 8 funds show negative alphas, with 4 of them being statistically 
significant at a 5% level. The highest adjusted R2 is obtained when using the Dow 
Jones US Healthcare Index as benchmark and has a value of 99.99%. 
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Table 6 – Fund performance using the conditional single model 
This table presents regression estimates for both equally weighted portfolios and value weighted portfolios with the Dow Jones US Healthcare Index as benchmark (panel A) 
and the general market index as benchmark (panel B) using the full conditional one factor model during period from 31/01/2002 to 30/09/2014. It shows abnormal 
performance estimates (conditional alphas), conditional systematic risk (betas) and the adjusted coefficient of determination (Adj. Rsq). Three predetermined public 
information variables are used: the short term interest rate level (tb), the slope of term spread (ts) and the dividend yield (dy).  Wald 1, Wald 2 and Wald 3 correspond to the 
null hypothesis that the coefficients of conditional alphas, conditional betas, and conditional alphas and conditional betas, respectively, are jointly equal to zero. Standard 
errors are corrected, whenever appropriate, for the presence of heteroskedasticity using the correction presented by White (1980), or for the presence of autocorrelation and 
heteroskedasticity using the procedure suggested by Newey and West (1987). t-statistics are presented in parenthesis. Asterisks (***, **, *) indicate statistically significant 
values at the 1%, 5% and 10% levels, respectively. The number of individual funds presenting positive (N+) and negative (N-) alphas is reported, the number of those which 
are statistically significant at the 5% level are reported in brackets.  
 
  αp αp,tb αp,ts  αp,dy βp,0 βp,tb βp,ts βp,dy Adj Rsq Wald 1 Wald 2 Wald 3 
Panel A: Benchmark Dow 
Jones US Healthcare Index 
 
     
  
    
Equally weighted portfolio 0.0021 -0.0013 -0.0029 -0.0048 1.0103 0.0104 0.0739 -0.0723 86.67% 0.429 219.71*** 142.167*** 
 (1.632) (-0.334) (-0.763) (-0.776) (27.54)*** (0.093) (0.838) (-0.540)     
Value weighted portfolio 0.0023 -0.0013 -0.0039 -0.0046 1.0595 0.0527 0.1211 -0.0583 82.13% 0.485 155.581*** 100.821*** 
 (1.387) (-0.278) (-0.837) (-0.595) (23.183)*** (0.377) (1.103) (-349)     
N + 28(4)           
N - 7(2)            
              
Panel B: General Market 
Index 
 
   
      
  
Equally weighted portfolio 0.0036 -0.0039 -0.0068 -0.0025 0.8096 0.1608 0.2152 -0.1487 65.85% 0.471 63.39*** 46.063*** 
 (1.747)* (-0.645) (-1.105) (-0.216) (13.771)*** (0.920) (1.567) (-0.620)     
Value weighted portfolio 0.0039 -0.0039 -0.0078 -0.0023 0.8432 0.1605 0.2173 -0.1822 61.39% 0.6 52.511*** 35.520*** 
 (1.6242) (-0.561) (-1.141) (-0.199) (13.285)*** (0.856) (1.513) (-0.831)     
N + 34(13)            
N - 1(0)            
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The conditional four factor model indicates that only the additional risk factor 
that has statistically significant betas at a 1% level is the HML factor, meaning that the 
funds are mainly exposed to growth companies. 
Additionally, the results of the Wald test for conditional alphas show that there 
is no evidence of time-varying alphas. This finding suggests that that the performance 
of the portfolios does not vary over time according to predetermined public 
information variables. However, we can reject the null hypothesis of the conditional 
betas being jointly equal to zero, which indicates that risk varies over time according 
to public information variables. Likewise, the null hypothesis of the conditional alphas 
and conditional betas being jointly equal to zero for all portfolios can also be rejected. 
The importance of incorporating the public information variables in the performance 
assessment models is reinforced through these results. 
The explanatory power of the conditional four factor models is improved when 
compared to the unconditional Carhart (1997) four factor models and the conditional 
single index models, which is consistent with the empirical evidence of 
Christopherson, Ferson and Glassman (1998) and Ferson and Schadt (1996). 
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Table 7 – Fund performance using the conditional four factor model 
This table presents regression estimates for both equally weighted portfolios and value weighted portfolios with the Dow Jones US Healthcare Index as benchmark (panel A) and the general 
market index as benchmark (panel B) using the full conditional four factor model during period from 31/01/2002 to 30/09/2014. It shows abnormal performance estimates (conditional alphas), 
conditional systematic risk (betas), the regressions coefficients of Size (p,s), Value (p,h), and Momentum (p,m) factors and the adjusted coefficient of determination (Adj. Rsq). Wald indicates the 
result of the Wald test for the null hypothesis that the coefficients of the market, size, book-to-market and momentum factors are jointly equal to zero. Three predetermined public information 
variables are the short term interest rate level (tb), the slope of term spread (ts) and the dividend yield (dy). Wald 1, Wald 2 and Wald 3 correspond to the null hypothesis that the coefficients of 
conditional alphas, conditional betas, conditional alphas and conditional betas, respectively, being jointly equal to zero. Standard errors are corrected, whenever appropriate, for the presence of 
heteroskedasticity using the correction presented by White (1980), or for the presence of autocorrelation and heteroskedasticity using the procedure suggested by Newey and West (1987). t-
statistics are presented in parenthesis. Asterisks (***, **, *) indicate statistically significant values at the 1%, 5% and 10% levels, respectively. The number of individual funds presenting positive 
(N+) and negative (N-) alphas is reported, the number of those which are statistically significant at the 5% level are reported in brackets. 
 αp0 αp,tb αp,ts αp,dy βp0 βp,tb βp,ts βp,dy βp,s βp,s,tb βp,s,ts βp,s,dy βp,h βp,h,tb βp,h,ts βp,h,dy βp,m βp,m,tb βp,m,ts βp,m,dy 
Adi. 
Rsq 
Wald 
1 
Wald 
2 
Wald 
3 
Panel A: Benchmark Dow Jones US Healthcare Index 
Equally weighted  0.0023 0.0006 -0.001 -0.004 0.9643 0.0193 0.101 -0.066 0.4175 -0.064 -0.118 -0.141 -0.184 -0.217 -0.2513 -0.2364 -0.023 0.0445 0.0018 0.0305 92.9% 0.674 
454 
*** 
491 
*** 
portfolio (2.29) 
** 
(0.18) (-0.43) (-0.855) (38)*** (0.24) (1.54) (-0.66) (8.4)*** (-0.43) (-0.94) (-0.65) 
(-3.84) 
*** 
(-1.64) (-1.17)** (-1.17) (-0.60) (0.41) (0.01) (0.33)     
Value weighted  0.0025 0.001 -0.002 -0.0074 1.0031 0.082 0.190 0.033 0.4396 
-
0.095 
-0.21 -0.26 -0.282 
-
0.264 
-0.3176 -0.382 -0.02 0.045 0.025 -0.01 89% 1.171 
72.03
*** 
68.01 
*** 
portfolio (1.92)* (0.35) (-0.4) (-1.1) (26)*** (0.72) (1.9)* (0.23) (7.9)*** (-0.5) (-1.3) (-1.2) 
(-4.5) 
*** 
(-1.4) (-2.3)** (-1.36) (-0.5) (0.37) (0.23) (-0.1)     
N + 27 (6)                        
N - 8 (4)                        
                         
Panel B: General Market Index 
Equally weighted  0.0058 -0.001 -0.002 -0.0022 0.8329 0.265 0.252 0.049 0.1367 -0.35 -0.02 0.029 -0.415 -0.46 -0.4596 -0.261 -0.03 0.09 -0.08 0.284 71% 0.062 
20.74 
*** 
20.25 
*** 
Portfolio (2.8) 
*** 
(-0.3) (-0.4) (-0.21) 
(13.3) 
*** 
(1.46) (1.7)* (0.17) (1.48) (-1.2) (-0.1) (0.08) 
(-4.3) 
*** 
(-1.6) (-1.89)* (-0.54) (-0.5) (0.49) (-0.5) (1.8)*     
Value weighted  0.0064 -0.0002 -0.002 -0.005 0.8527 0.267 0.283 0.136 0.1595 -0.37 -0.08 -0.04 
-
0.5239 
-0.53 -0.5382 -0.49 -0.03 0.08 -0.08 0.247 67% 0.137 
17.71 
*** 
17.3 
*** 
portfolio (2.8) 
*** 
(-0.1) (-0.3) (-0.42) 
(11.9) 
*** 
(1.29) (1.7)* (0.43) (1.52) (-1.1) (-0.3) (0.11) 
(-4.8) 
*** 
(-1.6) (-1.95)* (-0.88) (-0.4) (0.38) (-0.4) (1.36)     
N + 35 (14)                        
N - 0(0)                        
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5.2. Performance persistence 
In this section, we analyze the performance persistence of healthcare mutual 
funds to analyze whether past performance can help predict future performance or not.  
To evaluate the performance persistence, we use two different approaches: 
cross-sectional regressions and contingency tables. We use three different periods of 
analysis:  6 months, 12 months and 24 months, to test performance persistence over 
shorter and longer periods. 
The assessment of persistence is based on risk-adjusted alphas obtained 
through the unconditional four factor model of Carhart (1997). 
 
5.2.1. Cross-sectional regressions 
This approach to measure persistence is based on cross-sectional regressions 
that are used to analyze the relationship of future performance with past performance. 
With a significant positive t-statistic for the slope coefficient, we can reject the null 
hypothesis of no persistence of performance, thereby concluding that there is evidence 
of persistence or future performance is related to past performance. 
The results of the cross-sectional regressions (as in Fama and MacBeth, 1973) 
between the future alphas and the past alphas for the periods of 6 months, 12 months 
and 24 months are reported in table 8.   
Table 8 shows strong evidence of performance persistence for the period of 6 
months. For this time period, the regression coefficients are positive and statistically 
significant at a 5% level. Looking at the statistics for the periods of 12 and 24 months, 
we observe that the slope coefficient for the period of 12 months is negative, while the 
slope coefficient for the period of 24 months is positive, but none of them are 
statistically significant. We can therefore conclude that there is no evidence of 
persistence for 12 and 24 month periods.  
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Table 8 – Performance persistence: Cross-sectional regressions 
This table reports the statistics for the cross-sectional regressions (as in Fama and MacBeth, 1973) 
between the future alphas and past alphas for periods 6 months, 12 months and 24 months from January 
2004 to June 2014. Monthly alphas are obtained through the unconditional four factor model. t-statistics 
are presented in parenthesis. Asterisks (***, **, *) indicate statistically significant values at the 1%, 5% 
and 10% levels, respectively. 
Periods 
Unconditional four factor model 
a t-stat b t-stat 
6 months 0.833 9.885*** 0.220 2.691** 
12 months 1.039 4.632*** -0.022 -0.097 
24 months 0.812 2.510* 0.213 0.626 
 
5.2.2. Contingency tables 
The contingency tables are a non-parametric methodology widely used to 
assess the existence of performance persistence. As mentioned before, the null 
hypothesis of no persistence will be rejected if we find statistical evidence that winners 
in one period remain winner in the next period.  
Table 9 presents the contingency table results for periods of 6 months for the 
second semester of 2004 to the first semester of 2004. Similar to the results obtained 
with the cross-sectional regressions, we find strong evidence of persistence. The 
percentage of repeat winners is more than 50% and Malkiel’s (1995) Z-statistic is 
statistically significant at a 5% level. Likewise, Brown and Goetzmann’s (1995) Odds 
ratio is greater than 1, and its Z-statistic is statistically significant at a 5% level. 
Moreover, Kahn and Rudd’s (1995) Chi-square statistic shows statistically significant 
persistence at a 5% level as well. 
Look at the individual periods in the table 9, we find that there is persistence of 
positive performance in 2 out of the 20 periods with Malkiel’s (1995) Z-test. By 
Brown and Goetzmann’s (1995) Odds ratio Z-statistic test and Kahn and Rudd’s 
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(1995) Chi-square test, we conclude that 3 of the 20 periods show statistically 
significant persistence at a 5% level.  
Table 9 – Performance persistence: Contingency table for periods of 6 months 
This table presents the results of the contingency table for 6 months based on unconditional multi-index 
alphas for the second semester of 2004 to the first semester of 2014. WW indicates funds that were 
winners in two subsequent periods; WL indicates funds that were winners in one period and losers in the 
next period; LW indicates funds that were losers in one period and winners in the next period; WW 
indicates funds that were losers in two subsequent periods. The % RW refers to the percentage of 
repeated winners as in Malkiel (1995). The Odd ratio is calculated as in Brown and Goetzmann (1995). 
The Z statistic and corresponding P-value are also reported. Chi refers to the chi-square test as in Kahn 
and Rudd (1995) and Yate’s P-value is the corresponding p-value considering the Yate correction for 
continuity. Values in the bold refer to statistical significance at the 5% level. 
 
Periods WW LW WL LL 
Malkiel Brown and Goetzmann Kahn and Rudd 
% 
RW 
Z 
P-
value 
Odds 
ratio 
Z P-value Chi 
Yate’s  
P-value 
1 2 5 4 4 5 0.56 0.33 0.739 1.56 0.47 0.638 0.22 1.000 
2 3 4 6 6 3 0.40 -0.63 0.527 0.33 -1.15 0.251 1.42 0.483 
3 4 7 3 3 6 0.70 1.26 0.206 4.67 1.56 0.119 2.68 0.255 
4 5 9 1 1 8 0.90 2.53 0.011 72.0 2.86 0.004 11.95 0.003 
5 6 6 4 4 5 0.60 0.63 0.527 1.88 0.68 0.500 0.58 0.827 
6 7 7 4 4 6 0.64 0.90 0.366 2.63 1.07 0.283 1.29 0.518 
7 8 7 4 4 6 0.64 0.90 0.366 2.63 1.07 0.283 1.29 0.518 
8 9 5 6 6 4 0.45 -0.30 0.763 0.56 -0.66 0.507 0.52 0.819 
9 10 7 4 4 6 0.64 0.90 0.366 2.63 1.07 0.283 1.29 0.518 
10 11 5 6 6 4 0.45 -0.30 0.763 0.56 -0.66 0.507 0.52 0.819 
11 12 5 6 6 4 0.45 -0.30 0.763 0.56 -0.66 0.507 0.52 0.819 
12 13 7 4 4 7 0.64 0.90 0.366 3.06 1.26 0.207 1.64 0.394 
13 14 8 4 4 7 0.67 1.15 0.248 3.50 1.43 0.153 2.22 0.300 
14 15 10 3 2 8 0.83 2.31 0.021 13.3 2.52 0.012 7.78 0.022 
15 16 7 10 10 7 0.41 -0.73 0.467 0.49 -1.02 0.306 1.06 0.493 
16 17 12 5 5 12 0.71 1.70 0.090 5.76 2.33 0.020 5.76 0.040 
17 18 10 7 7 10 0.59 0.73 0.467 2.04 1.02 0.306 1.06 0.493 
18 19 8 9 9 8 0.47 -0.24 0.808 0.79 -0.34 0.732 0.12 1.000 
19 20 9 8 8 9 0.53 0.24 0.808 1.27 0.34 0.732 0.12 1.000 
20 21 8 9 9 8 0.47 -0.24 0.808 0.79 -0.34 0.732 0.12 1.000 
Total 146 107 106 133 0.58 2.52 0.01 1.71 2.95 0.003 9.54 0.004 
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In table 10, we display the contingency table results for periods of 12 months.  
Table 10 – Performance persistence: Contingency table for periods of 12 months 
This table presents the results of the contingency table for 12 months based on unconditional multi-
index alphas for the period of January 2005 to December 2013. WW indicates funds that were winners 
in two subsequent periods; WL indicates funds that were winners in one period and losers in the next 
period; LW indicates funds that were losers in one period and winners in the next period; WW indicates 
funds that were losers in two subsequent periods. The % RW refers to the percentage of repeated 
winners as in Malkiel (1995). The Odd ratio is calculated as in Brown and Goetzmann (1995). The Z 
statistic and corresponding P-value are also reported. Chi refers to the chi-square test as in Kahn and 
Rudd (1995) and Yate’s P-value is the corresponding p-value considering the Yate correction for 
continuity. Values in the bold refer to statistical significance at the 5% level. 
 
Periods WW LW WL LL 
Malkiel 
Brown and 
Goetzmann 
Kahn and Rudd 
% 
RW 
Z 
P-
value 
Odds 
ratio 
Z 
P-
value 
Chi 
Yate’s  
P-value 
1 2 6 3 3 6 0.67 1.00 0.317 4.00 1.39 0.166 2.00 0.346 
2 3 7 3 3 6 0.70 1.26 0.206 4.67 1.56 0.119 2.68 0.255 
3 4 7 3 3 6 0.70 1.26 0.206 4.67 1.56 0.119 2.68 0.255 
4 5 2 9 9 1 0.18 -2.11 0.035 0.02 -2.82 0.005 10.81 0.004 
5 6 4 7 7 3 0.36 -0.90 0.366 0.24 -1.51 0.131 2.43 0.270 
6 7 7 3 4 7 0.64 0.90 0.366 4.08 1.51 0.131 2.43 0.270 
7 8 7 5 5 6 0.58 0.58 0.564 1.68 0.62 0.538 0.48 0.842 
8 9 11 6 6 11 0.65 1.21 0.225 3.36 1.69 0.091 2.94 0.170 
9 10 14 3 3 14 0.82 2.67 0.008 21.78 3.42 0.001 14.24 0.001 
Total 65 42 43 60 0.60 2.12 0.034 2.16 2.74 0.006 7.87 0.009 
In contrast with the results obtained with the cross-sectional regressions, at the 
aggregate level the three tests used show evidence of persistence for periods of 12 
months.  
At the individual period level, there is statistically significant evidence at 1% 
level of persistence in 1 out of 9 periods with Malkiel’s (1995) Z-test and Brown and 
Goetzmann’s (1995) Odds ratio Z-statistic test. Using the Chi-square test of Kahn and 
Rudd’s (1995), we conclude that 2 out of the 9 periods show statistically significant 
persistence at a 1% level. 
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For periods of 24 months, the results of contingency table for January 2005 to 
December 2013 are reported in table 11. Similar to the results obtained with cross-
sectional regressions, for the aggregate level we cannot reject the null hypothesis of no 
persistence for periods of 24 months. However, at the individual level, we find 
evidence of persistence in 1 out of 4 periods on the basis of Brown and Goetzmann’s 
(1995) Odds ratio Z-statistic test.  
Table 11 – Performance persistence: Contingency table for periods of 24 months 
This table presents the results of the contingency table for 24 months based on unconditional multi-
index alphas for January 2006 to December 2013. WW indicates funds that were winners in two 
subsequent periods; WL indicates funds that were winners in one period and losers in the next period; 
LW indicates funds that were losers in one period and winners in the next period; WW indicates funds 
that were losers in two subsequent periods. The % RW refers to the percentage of repeated winners as in 
Malkiel (1995). The Odd ratio is calculated as in Brown and Goetzmann (1995). The Z statistic and 
corresponding P-value are also reported. Chi refers to the chi-square test as in Kahn and Rudd (1995) 
and Yate’s P-value is the corresponding p-value considering the Yate correction for continuity. Values 
in the bold refer to statistical significance at the 5% level. 
 
Periods WW LW WL LL 
Malkiel Brown and Goetzmann Kahn and Rudd 
% 
RW 
Z 
P-
value 
Odds 
ratio 
Z 
P-
value 
Chi 
Yate’s  
P-
value 
1 2 4 5 5 4 0.44 -0.33 0.739 0.64 -0.47 0.638 0.22 1.000 
2 3 4 6 6 3 0.40 -0.63 0.527 0.33 -1.15 0.251 1.42 0.483 
3 4 5 5 6 5 0.45 -0.30 0.763 0.83 -0.21 0.835 0.14 0.819 
4 5 8 2 4 9 0.67 1.15 0.248 9.00 2.21 0.027 5.70 0.055 
Total 21 18 21 21 0.50 0.00 1.00 1.17 0.35 0.729 0.33 0.902 
 To summarize this analysis of contingency table approach, we found evidence 
of performance persistence for two periods of 6 and 12 months. However, for longer 
periods of 24 months, there is no evidence of persistence. 
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6 - CONCLUSIONS 
The performance evaluation of actively managed mutual funds has been one of 
the most attractive debate topics in finance. Moreover, the assessment of performance 
persistence is also an important topic for fund managers and investors. However, most 
of studies on mutual fund performance investigate the abnormal performance and the 
persistence of performance for well-diversified funds, and only a few studies evaluate 
sector-specific funds. Currently, there are very few studies which focus on healthcare 
funds. This dissertation aims to contribute to the literature by evaluating the 
performance and the persistence of performance of this type of funds, which have a 
very specific risk and return characteristics. 
In this dissertation we examine the performance of 35 US equity sector 
healthcare mutual funds over the period of January 2002 to September 2014. Fund 
performance is evaluated based on the Jensen (1968) and Carhart (1997) unconditional 
measures as well as the full conditional model of Christopherson, Ferson and 
Glassman (1998). Three predetermined public information variables are used to proxy 
for market conditions: the lagged measure of the level of short-term interest rate, the 
lagged measure of the slope of the term spread and the lagged dividend yield of a 
market index. We used the Dow Jones US Healthcare Index and a general market 
index as benchmarks in each model.  
In terms of overall performance, the results suggest that healthcare funds show 
neutral performance relative to the Healthcare Index. In each model, the equally 
weighted and value weighted portfolios exhibit neutral performance as well. The 
neutral performance of mutual funds is thus consistent with most previous empirical 
evidence. Most of funds present positive alphas but just few funds are significant at a 
5% level. Furthermore, as in Cortez, Silva and Areal (2009), Bauer, Derwall and Otten 
(2007), and Areal, Cortez and Silva (2013), our results also indicate that conditional 
models lead to better regression estimates than unconditional models. The performance 
of the equally and value weighted portfolios is positive when we apply the 
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unconditional four factor model with the general market index benchmark. In fact, the 
performance of the portfolios is always better when using the general market index as 
benchmark than when using the Dow Jones US Healthcare Index as benchmark, which 
indicates that healthcare mutual funds outperform the market. We observe higher 
adjusted coefficient of determination when using the Dow Jones US Healthcare Index 
than when using general market index. Additionally, the equally weighted portfolios 
have adjusted R2 greater than the value weighted portfolios. The explanatory power of 
the conditional four factor models is higher when compared to the unconditional 
Carhart (1997) four factor models and the conditional single models, which is 
consistent with the empirical evidence of Christopher, Ferson and Glassman (1998) 
and Ferson and Schadt (1996). 
 Furthermore, our results suggest that US healthcare mutual funds are exposed 
to small stocks and growth stocks. This result confirms that the size and book-to-
market effects need to be controlled for, besides market risk. We also find that there is 
no evidence of time-varying conditional alphas while there is some evidence of time-
varying betas, which means the performance of the portfolios does not vary over time 
according to predetermined public information variables, but the risk varies over time 
according to public information variables. These results reinforce the importance of 
incorporating the public information variables in the performance evaluation models, 
as motivated by Fama and French (1989). 
The persistence phenomenon was assessed over periods of 6 months, 12 
months, and 24 months by using both cross-sectional regressions and the contingency 
tables methodologies. The results of the cross-sectional regression between the future 
alphas and past alphas show that there is evidence of persistence for periods of 6 
months, but there is no evidence of persistence for the periods of 12 and 24 months. 
Using the contingency table approach, we test the null hypothesis of no performance 
persistence by means of the Z-test for repeat winners, Odds ratio Z-statistic and Chi-
square test for independence, as well as Yates’s continuity correction to adjust for the 
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small sample bias. We find some evidence of persistence for 6 month and 12 month 
periods, but no persistence for 24 month periods. 
The main limitation of this study is that the dataset is not survivorship bias free 
and the number of healthcare funds is small. Another limitation is that the management 
fees in healthcare mutual funds have not been considered and so we did not evaluate 
the effect of this factor on fund performance. We suggest that further research might 
consider more sector fund categories and the effects of management fees on assessing 
fund performance. 
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Appendix 1 – List of US equity sector healthcare mutual funds 
This appendix shows the list of 35 US equity sector healthcare mutual funds obtaining from CRSP for period from January 2002 to September 2014. Lipper_class H: Health/ 
Biotechnology funds; Lipper_asset EQ: Equity; TNA: Total net assets at 9/30/2014 
Fund's 
number 
Name of fund Lipper_class Lipper_asset Start date Last date TNA 
3929 
Alger Funds: Alger Health Sciences Fund; Class A 
Shares 
H EQ 4/30/2002 9/30/2014 16,619 
4606 
Allianz Funds: AllianzGI Wellness Fund; Class D 
Shares 
H EQ 12/31/1996 9/30/2014 21,165 
6299 
BlackRock Funds: BlackRock Health Sciences 
Opportunities Portfolio; Investor A Shares 
H EQ 11/30/1999 9/30/2014 91,602 
8447 
Deutsche Securities Trust: Deutsche Health and 
Wellness Fund; Class S Shares 
H EQ 3/31/1998 9/30/2014 26,065 
11655 
Fidelity Advisor Series VII: Fidelity Advisor 
Biotechnology Fund; Class T Shares 
H EQ 3/31/1998 9/30/2014 3,549 
11685 
Fidelity Advisor Series VII: Fidelity Advisor Health 
Care Fund; Class T Shares 
H EQ 9/30/1996 9/30/2014 37,480 
12026 Fidelity Select Portfolios: Health Care Portfolio H EQ 7/31/1981 9/30/2014 423,844 
12042 
Fidelity Select Portfolios: Medical Equipment and 
Systems Portfolio 
H EQ 4/30/1998 9/30/2014 160,415 
12059 Fidelity Select Portfolios: Medical Delivery Portfolio H EQ 6/30/1986 9/30/2014 89,331 
12066 Fidelity Select Portfolios: Biotechnology Portfolio H EQ 12/31/1985 9/30/2014 442,368 
13058 
Franklin Strategic Series: Franklin Biotechnology 
Discovery Fund; Class A Shares 
H EQ 9/30/1997 9/30/2014 108,332 
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Fund's 
number 
Name of fund Lipper_class Lipper_asset Start date Last date TNA 
15402 ICON Funds: ICON Healthcare Fund; Class S Shares H EQ 2/28/1997 9/30/2014 36,715 
15659 
Voya Investors Trust: VY BlackRock Health 
Sciences Opportunities Portfolio; Service Class 
Shares 
H EQ 5/28/2004 6/30/2014 24,143 
16962 
Prudential Sector Funds, Inc: Prudential Jennison 
Health Sciences Fund; Class A Shares 
H EQ 5/28/1999 9/30/2014 61,661 
22635 
Oak Associates Funds: Live Oak Health Sciences 
Fund 
H EQ 5/31/2001 9/30/2014 4,233 
24800 T Rowe Price Health Sciences Fund, Inc H EQ 12/29/1995 9/30/2014 446,843 
27324 
Rydex Series Funds: Health Care Fund; Investor 
Class Shares 
H EQ 4/30/1998 9/30/2014 8,282 
27337 
Rydex Series Funds: Biotechnology Fund; Investor 
Class Shares 
H EQ 4/30/1998 9/30/2014 29,823 
27949 
Saratoga Advantage Trust: Health & Biotechnology 
Portfolio; Class A Shares 
H EQ 6/30/1999 9/30/2014 4,014 
28136 Schwab Capital Trust: Schwab Health Care Fund H EQ 6/30/2000 9/30/2014 58,368 
30885 VALIC Company I: Health Sciences Fund H EQ 5/31/2007 9/30/2014 23,734 
36331 
Delaware Group Equity Funds IV: Delaware 
Healthcare Fund; Class A Shares 
H EQ 8/31/2007 9/30/2014 4,181 
38766 
AIM Variable Insurance Funds (Invesco Variable 
Insurance Funds): Invesco VI Global Health Care Fd; 
Srs I Shs 
H EQ 9/30/2008 9/30/2014 10,016 
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Fund's 
number 
Name of fund Lipper_class Lipper_asset Start date Last date TNA 
38965 
Putnam Variable Trust: Putnam VT Global Health 
Care Fund; Class IB Shares 
H EQ 9/30/2008 9/30/2014 5,239 
39130 Rydex Variable Trust: Biotechnology Fund H EQ 9/30/2008 9/30/2014 1,334 
39136 Rydex Variable Trust: Health Care Fund H EQ 9/30/2008 9/30/2014 1,498 
39583 ProFunds: ProFund VP Biotechnology H EQ 9/30/2008 9/30/2014 (941) 
39586 ProFunds: ProFund VP Health Care H EQ 9/30/2008 9/30/2014 (230) 
39617 
John Hancock Variable Insurance Trust: Health 
Sciences Trust; Series I Shares 
H EQ 9/30/2008 9/30/2014 5,037 
39660 
Pacific Select Fund: Health Sciences Portfolio; Class 
I Shares 
H EQ 7/31/2008 9/30/2014 10,905 
40023 
T Rowe Price Equity Series, Inc: T Rowe Price 
Health Sciences Portfolio-II 
H EQ 9/30/2008 9/30/2014 7,571 
40027 ProFunds: ProFund VP Pharmaceuticals H EQ 9/30/2008 9/30/2014 (1,243) 
41102 
Variable Insurance Products Fund IV: Health Care 
Portfolio; Investor Class Shares 
H EQ 9/30/2008 9/30/2014 9,844 
48020 
JNL Variable Fund LLC: JNL/Mellon Capital 
Healthcare Sector Fund; Class B Shares 
H EQ 3/31/2004 9/30/2014 (268) 
53239 
John Hancock Funds II: Health Sciences Fund; Class 
NAV Shares 
H EQ 9/30/2011 9/30/2014 17,814 
 
